Performance of Urine Test in Patients Monitored for Recurrence of Bladder Cancer: A Multicenter Study in the United States

Messing, Edward M.; Teot, Lisa A.; Korman, Howard; Underhill, Eanne; Barker, Edward A.; Stork, Brian; Qian, Junqi; Bostwick, David G.

doi:10.1097/01.ju.0000173918.84006.4d

Cited by 74 publications

(61 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The monoclonal antibody 19A211 detects high molecular weight carcinoembryonic antigen, whereas M344 and LDQ10 detect a cancer-related mucin. According to one recent report, the test has a sensitivity of 81% and specificity of 75% in detecting bladder cancer (258 ). The ImmunoCyt test was evaluated in several earlier investigations (259,260 ) with similar findings (259,260 ).…”

Section: Monitoring Of Patients With Bladder Cancermentioning

confidence: 99%

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers

et al. 2010

View full text Add to dashboard Cite

Background: Updated National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed. Methods: Published reports relevant to use of tumor markers for 4 cancer sites—liver, bladder, cervical, and gastric—were critically reviewed. Results: α-Fetoprotein (AFP) may be used in conjunction with abdominal ultrasound for early detection of hepatocellular carcinoma (HCC) in patients with chronic hepatitis or cirrhosis associated with hepatitis B or C virus infection. AFP concentrations >200 μg/L in cirrhotic patients with typical hypervascular lesions >2 cm in size are consistent with HCC. After a diagnosis of HCC, posttreatment monitoring with AFP is recommended as an adjunct to imaging, especially in the absence of measurable disease. Although several urine markers have been proposed for bladder cancer, none at present can replace routine cystoscopy and cytology in the management of patients with this malignancy. Some may, however, be used as complementary adjuncts to direct more effective use of clinical procedures. Although carcinoembryonic antigen and CA 19-9 have been proposed for use gastric cancer and squamous cell carcinoma antigen for use in cervical cancer, none of these markers can currently be recommended for routine clinical use. Conclusions: Implementation of these recommendations should encourage optimal use of tumor markers for patients with liver, bladder, cervical, or gastric cancers.

show abstract

Section: Monitoring Of Patients With Bladder Cancermentioning

confidence: 99%

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers

et al. 2010

View full text Add to dashboard Cite

show abstract

“…31 In general, studies suggest that ImmunoCyt/uCyt+ has superior sensitivity over cytology for pathological stage Ta-T2 and grade 1-2 tumours and similar or better sensitivity for grade 3 tumours and carcinoma in situ. 31,32,38 Unlike the molecular-based tests, ImmunoCyt/uCyt+ is relatively unaffected by benign conditions and instillation therapy. 57 Still, this test, like cytology, remains subjective and depends in part on the technician.…”

Section: Immunocyt/ucyt+mentioning

confidence: 99%

“…Specificity of the combined assay reaches 61.0%-77.7%, which is less than that offered by cytology alone. 27,[31][32][33]38,39 The ImmunoCyt/uCyt+ assay requires technical expertise, extensive sample handling and preparation and specialized equipment. However, a person with minimal cytology training and experience can perform the test.…”

Section: Immunocyt/ucyt+mentioning

confidence: 99%

“…Specificity of the Bladder Cancer Test is reported to be 60.0%-95.0%, and specificity of the NMP22 BladderChek is reportedly in the range of 40.0%-89.8%. 11,[19][20][21][22][23]25,26,32,34,36,37,[39][40][41][42] The NMP22 tests are based on the release of NMPs into the urine following apoptosis of the urothelial cells, a process that can also occur as a result of benign conditions. As is the case with the BTA tests, NMP22 levels are raised in patients with urinary tract infections, concurrent urolithiasis, history of bladder interposition, other malignancies, intravesical therapies and even cystoscopy, all of which may contribute to false-positive results.…”

Section: Nuclear Matrix Protein 22mentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers for detection and surveillance of bladder cancer

Budman

Kassouf

Steinberg

2013

CUAJ

126

View full text Add to dashboard Cite

Introduction: Bladder cancer is the fourth most common cancer in men and the ninth most common cancer in women in Canada. Early detection of tumours is essential for improved prognosis and long-term survival. The standard method for detection and surveillance is cystoscopy together with urine cytology. Cystoscopy is relatively sensitive but is expensive and invasive. Urinary cytology is a noninvasive method that has poor sensitivity but high specificity; it is relied on for the detection of carcinoma in situ. Currently, several urinary based bladder tumour biomarkers with USFDA/Health Canada approval are available commercially, but none have been widely adopted by urologists despite their offering high sensitivity and/or specificity. We present here a review of recent studies evaluating 7 commercial biomarker assays for the detection and/or surveillance of bladder cancer.Results: Sensitivity and specificity ranges, respectively, for each marker were reported as follows: BTA Stat (Polymedco), 52.5%–78.0% and 69.0%–87.1%; BTA Trak (Polymedco), 51%–100% and 73%–92.5%; cytology, 12.1%–84.6% and 78.0%–100%; hematuria dipstick, 47.0%–92.6% and 51.0%–84.0%; NMP22 Bladder Cancer Test (Matritech), 34.6%–100% and 60.0%–95.0%; NMP22 BladderChek (Matritech), 49.5%–65.0% and 40.0%–89.8%;ImmunoCyt/uCyt+ (DiagnoCure), 63.3%–84.9% and 62.0%–78.1%; ImmunoCyt/uCyt+ and cytology, 81.0%–89.3% and 61.0%–77.7%; and UroVysion (Abbott Molecular)/florescence in situ hybridization, 68.6%–100% and 65.0%–96.0%.Conclusion: We find that no currently available bladder cancer urinary marker is sensitive enough to eliminate the need for cystoscopy. In addition, cytology remains integral to the detection of occult cancer. However, owing to their relatively high sensitivities, these markers may be used to extend the period between cystoscopies in the surveillance of patients with transitional cell carcinoma. Further study is required to determine which markers, alone or in panel, would best accomplish this.

show abstract

“…Biochemical testing of urine should be able to diagnose early bladder carcinoma because candidate informative molecules could be excreted into the urine during cancer development. Proteomic profiling of urine has been suggested as a diagnostic test for bladder carcinoma 11 . In addition, many other biochemical molecules or genetic markers have been discovered that could be used to diagnose bladder carcinoma with fair sensitivity and specificity.…”

Section: Introductionmentioning

confidence: 99%

Biomarkers of Bladder Cancer in Urine: Evaluation of Diagnostic and Prognostic Significance of Current and Potential Markers

Dawam¹

2012

Bladder Cancer - From Basic Science to Robotic Surgery

View full text Add to dashboard Cite

Performance of Urine Test in Patients Monitored for Recurrence of Bladder Cancer: A Multicenter Study in the United States

Cited by 74 publications

References 17 publications

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers

Biomarkers for detection and surveillance of bladder cancer

Biomarkers of Bladder Cancer in Urine: Evaluation of Diagnostic and Prognostic Significance of Current and Potential Markers

Contact Info

Product

Resources

About